As an orally given agent for the first-line treatment of advanced post-menopausal ER+, HER2-negative breast cancer, used in combination with letrozole, was approved by the US Food and Drug Administration (FDA) in 2015 (9). The gene discussed is ESR1; the disease is breast cancer.